Crossref
Firm misled investors on Alzheimer’s drug, SEC charges
Science · 2024
DOI: 10.1126/science.adt5694 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science, 2024. Verfasst von Charles Piller. Hauptthemen laut MEDLINE: Alzheimer Disease, Drug Industry, Spiro Compounds, Scientific Misconduct. Die Arbeit wurde bisher 2-mal zitiert (Crossref).
Themen: Demenz
Abstract (Originalsprache)
Agency fines Cassava Sciences $40 million for touting flawed research on simufilam
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Alzheimer DiseaseDrug IndustrySpiro CompoundsScientific MisconductHumansInvestmentsUnited States
Substanzen
SimufilamSpiro Compounds
Zitieren
APA
Piller, C. (2024). Firm misled investors on Alzheimer’s drug, SEC charges. Science. https://doi.org/10.1126/science.adt5694
Vancouver
Piller C. Firm misled investors on Alzheimer’s drug, SEC charges. Science. 2024. doi:10.1126/science.adt5694
BibTeX
@article{Piller2024,
author = {Piller, Charles},
title = {Firm misled investors on Alzheimer’s drug, SEC charges},
journal = {Science},
year = {2024},
doi = {10.1126/science.adt5694}
}
EUVIMED